ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 0 مورد

Atoltivimab, maftivimab, and odesivimab (United States: Available via manufacturer expanded access or public health distribution): Pediatric drug information

Atoltivimab, maftivimab, and odesivimab (United States: Available via manufacturer expanded access or public health distribution): Pediatric drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
Therapeutic Category
  • Antiviral Agent;
  • Monoclonal Antibody
Dosing: Neonatal
Orthoebolavirus zairense infection

Orthoebolavirus zairense (formerly Zaire ebolavirus) infection (including newborns born to mothers RT-PCR positive for O. zairense infection): IV: 50 mg/kg each of atoltivimab, maftivimab, and odesivimab as a single dose.

Dosing: Pediatric
Orthoebolavirus zairense infection

Orthoebolavirus zairense (formerly Zaire ebolavirus) infection: Infants, Children, and Adolescents: IV: 50 mg/kg each of atoltivimab, maftivimab, and odesivimab as a single dose.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Adult

(For additional information see "Atoltivimab, maftivimab, and odesivimab (United States: Available via manufacturer expanded access or public health distribution): Drug information")

Orthoebolavirus zairense [formerly Zaire ebolavirus] infection

Orthoebolavirus zairense [formerly Zaire ebolavirus] infection : IV: 50 mg/kg each of atoltivimab, maftivimab, and odesivimab as a single dose (Ref).

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Cardiovascular: Hypotension (15%), tachycardia (20%)

Endocrine & metabolic: Increased serum potassium (13%)

Gastrointestinal: Diarrhea (11%), vomiting (19%)

Hepatic: Increased serum aspartate aminotransferase (21%)

Nervous system: Chills (39%)

Renal: Increased serum creatinine (15%)

Respiratory: Tachypnea (19%)

Miscellaneous: Fever (54%)

1% to 10%:

Endocrine & metabolic: Decreased serum potassium (9%), decreased serum sodium (7%), increased serum sodium (9%)

Hepatic: Increased serum alanine aminotransferase (10%)

Respiratory: Hypoxia (10%)

Postmarketing:

Hypersensitivity: Hypersensitivity reaction

Miscellaneous: Infusion related reaction

Contraindications

There are no contraindications listed in the manufacturer's labeling.

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity reactions: Hypersensitivity reactions, including life-threatening infusion-related reactions, have been reported during and after receipt of atoltivimab, maftivimab, and odesivimab. May slow or interrupt infusion for any signs of infusion-related reaction or other adverse effects; immediately discontinue for severe or life-threatening hypersensitivity reaction.

Other warnings/precautions:

• Immunizations: Avoid concurrent administration of a live vaccine during treatment with atoltivimab, maftivimab, and odesivimab.

Product Availability

Inmazeb: FDA approved October 2020. Product will not be commercially available; will only be distributed for a public health emergency in the US.

Prescribing and Access Restrictions

Regeneron will provide atoltivimab, maftivimab, and odesivimab in response to outbreaks in the Democratic Republic of the Congo through the Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) protocol for compassionate use and is actively working with non-governmental agencies to ensure continued access to atoltivimab, maftivimab, and odesivimab in low- and middle-income countries. See inmazeb.com for more information.

Administration: Pediatric

IV: Must be diluted prior to administration. Allow diluted infusion to reach room temperature prior to administration; preparations diluted with D5W may be infused at temperatures up to 35°C (95°F), if temperature is >25°C (77°F) administer immediately after preparation. Administer through an IV line containing a 0.2-micron filter. Infusion time is based on patient weight. Slow or interrupt infusion if the patient develops any signs of infusion-associated events (eg, hypotension, chills, fever elevation) or other adverse events; if severe or life-threatening hypersensitivity reactions occur, immediately discontinue infusion and provide emergency care.

Infusion duration based on patient weight:

0.5 to <2 kg: Infuse over 4 hours.

2 to <16 kg: Infuse over 3 hours.

16 to <150 kg: Infuse over 2 hours.

≥150 kg: Infuse over 4 hours.

Administration: Adult

IV: Allow diluted infusion solution to come to room temperature prior to administration; preparations diluted with D5W may be infused at temperatures up to 35°C (95°F); if temperature is >25°C (>77°F) administer immediately after preparation. Administer IV with 0.2-micron filter. Infusion rate is based on total volume: for 250 mL to 1 L, infuse over 2 hours; for 2 L, infuse over 4 hours. May slow or interrupt infusion for signs of infusion-associated events or other adverse events.

Storage/Stability

Prior to dilution: Store intact vials at 2°C to 8°C (36°F to 46°F). Protect from light; do not freeze or shake.

After dilution:

Diluted with NS: Store at room temperature up to 25°C (77°F) for no more than 8 hours or at 2°C to 8°C (36°F to 46°F) for no more than 24 hours. Do not freeze.

Diluted with D5W: Store at room temperature up to 25°C (77°F) for no more than 4 hours or at 2°C to 8°C (36°F to 46°F) for no more than 24 hours. Do not freeze.

Diluted with LR: Store at room temperature up to 25°C (77°F) or at 2°C to 8°C (36°F to 46°F) for no more than 4 hours. Do not freeze.

Use

Treatment of infection caused by Orthoebolavirus zairense (formerly Zaire ebolavirus) (FDA approved in all ages).

Limitations of use: Efficacy not established for other species of the Orthoebolavirus (formerly Ebolavirus) and Orthomarburgvirus (formerly Marburgvirus) genera.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Ebola Zaire Vaccine (Live): Ebola-Directed Monoclonal Antibodies may decrease therapeutic effects of Ebola Zaire Vaccine (Live). Management: Wait several months (3 to 6 months, and up to 11 months) after use of Ebola-directed antibodies before administering the live Ebola Zaire vaccine. Repeat vaccination may be required if antibody therapy and vaccination cannot be adequately separated. Risk D: Consider Therapy Modification

Efgartigimod Alfa: May decrease therapeutic effects of Fc Receptor-Binding Agents. Risk C: Monitor

Nipocalimab: May decrease therapeutic effects of Fc Receptor-Binding Agents. Risk C: Monitor

Rozanolixizumab: May decrease therapeutic effects of Fc Receptor-Binding Agents. Risk C: Monitor

Pregnancy Considerations

Atoltivimab, maftivimab, and odesivimab are humanized IgG1κ monoclonal antibodies. Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).

Outcome data related to the use of atoltivimab, maftivimab, and odesivimab during pregnancy are limited (Mulangu 2019; Philpott 2023).

Following maternal infection, the Ebola virus crosses the placenta and can be detected in maternal body fluids and transmitted to the fetus. Ebola virus RNA can be detected in the amniotic fluid and fetal tissue for up to 32 days after maternal clearance of viremia (CDC 2024a). Maternal Ebola infection carries a high rate of mortality for both the fetus and the mother. Maternal Ebola virus infection typically results in miscarriage, stillbirth, and maternal and/or neonatal death (Olgun 2018). Treatment with atoltivimab/maftivimab/odesivimab for Ebola virus disease caused by O. zairense (formerly Zaire ebolavirus) should not be withheld due to pregnancy.

Pregnant health care providers should not care for patients with Ebola virus disease (CDC 2024a).

Monitoring Parameters

Monitor for hypersensitivity or infusion-related reactions (eg, hypotension, chills, elevation of fever) during and following infusion.

Mechanism of Action

Atoltivimab, maftivimab, and odesivimab is an antiviral drug combination of 3 recombinant human IgG1κ monoclonal antibodies, each targeting the O. zairense (formerly Zaire ebolavirus) glycoprotein, which mediates viral attachment and host membrane fusion. Atoltivimab, maftivimab, and odesivimab can bind to the glycoprotein simultaneously. Maftivimab is a neutralizing antibody that blocks viral entry into host cells. Odesivimab is a non-neutralizing antibody that induces antibody-dependent effector function through FcyRIIIa signaling when bound to target; odesivimab also binds to soluble O. zairense glycoprotein. Atoltivimab combines both neutralization and FcyRIIIa signaling activities.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Mean Vd, steady state: Atoltivimab: 58.2 mL/kg; Maftivimab: 57.6 mL/kg; Odesivimab: 56 mL/kg.

Half-life elimination: Atoltivimab: 21.2 days; Maftivimab: 22.3 days; Odesivimab: 25.3 days.

  1. Centers for Disease Control and Prevention (CDC). Clinical guidance for Ebola in people who are pregnant. https://www.cdc.gov/ebola/hcp/clinical-guidance/clinical-guidance-for-ebola-in-people-who-are-pregnant.html?CDC_AAref_Val=https://www.cdc.gov/vhf/ebola/clinicians/evd/pregnant-women.html. Updated May 3, 2024a. Accessed October 30, 2024.
  2. Centers for Disease Control and Prevention (CDC). Clinical guidance for neonates born to patients with suspected or confirmed Ebola disease. https://www.cdc.gov/ebola/hcp/clinical-guidance/clinical-guidance-for-neonates-born-to-patients-with-suspected-or-confirmed-ebola-disease.html. Updated May 21, 2024b. Accessed October 30, 2024.
  3. Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. Front Immunol. 2020;11:1920. doi:10.3389/fimmu.2020.01920 [PubMed 33013843]
  4. Inmazeb (atoltivimab, maftivimab, and odesivimab) [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals Inc; October 2024.
  5. Mulangu S, Dodd LE, Davey RT Jr, et al; PALM Consortium Study Team. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293-2303. doi:10.1056/NEJMoa1910993 [PubMed 31774950]
  6. Olgun NS. Viral infections in pregnancy: a focus on Ebola virus. Curr Pharm Des. 2018;24(9):993-998. doi:10.2174/1381612824666180130121946 [PubMed 29384053]
  7. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646. doi:10.1155/2012/985646 [PubMed 22235228]
  8. Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol. 2009;86(4):328-344. doi:10.1002/bdrb.20201 [PubMed 19626656]
  9. Philpott D, Rupani N, Gainey M, et al. Maternal, fetal, and perinatal outcomes among pregnant women admitted to an Ebola treatment center in the Democratic Republic of Congo, 2018-2020. PLoS One. 2023;18(9):e0286843. doi:10.1371/journal.pone.0286843 [PubMed 37682812]
  10. Refer to manufacturer’s labeling.
  11. World Health Organization (WHO). Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease. https://apps.who.int/iris/bitstream/handle/10665/330851/9789240001381-eng.pdf?ua=1. Published February 2020. Accessed October 30, 2024. [PubMed 32091684]
Topic 129868 Version 34.0